Platforms & Product
Benchling launches Science Foundries
Agents now run whole R&D workflows, with scientists approving key steps. Benchling calls agents its fastest-growing product.
Read the full story →Revvity Signals unveils LabGistics
AI turns plain-English SOPs into GxP-ready workflows from research to production, shipping in December.
Source: 20 Oct →Funding & M&A
OpenAI acquires Orchestra Bio
Drug-programme coordination agents are being folded into OpenAI’s Rosalind life sciences suite. The AI labs are now chasing R&D software budgets.
Source: 20 Oct →Albert Invent raises $55M
The chemistry R&D platform grew users 6x year on year, with customers including BASF, Henkel and Clorox.
Source: 15 Oct →Capital is concentrating
Q3’s biggest rounds went to AI platforms, including Chai Discovery ($400M) and Enveda ($311M). Investors are favouring fewer, later-stage bets.
Source: 7 Oct →Leadership Moves
Veeva
Dan Rizzo is now EVP Sales, Consulting & Services. Tom Schwenger has left to become CEO of a Veeva partner.
Source →Nuclera
Carl Raimond, formerly President of Proteomic Sciences at Thermo Fisher, is the new CEO.
Source →Revalia Bio
Casimir Starsiak III, formerly Eli Lilly’s enterprise AI and research software lead, is the new CEO.
Source →Talent Insight
The agent era needs a different commercial team
- Layoffs are down sharply, so fewer good people are on the market and they're harder to hire.
- We’re seeing more searches for Deployment Strategists, Forward Deployed Scientists and scientific CS, alongside VP Sales and CRO roles.
- For 2027 plans: For 2027 plans budget for deployment talent next to your AEs. Lab credibility plus AI fluency is the rarest combination.
jack@qpexec.com